MBTPS1 and multiple sclerosis: Specifically, we observed that two S1P receptor agonists FDA-approved for multiple sclerosis, fingolimod and ozanimod, and the more brain penetrant S1P<sub>1</sub> receptor agonist CYM5442, reduced binge alcohol drinking in the drinking in the dark (DID) paradigm in mice.